Back to search results

Heart Transplant Dysfunction Study with Regadenoson

This study is looking for better ways to detect problems with transplanted hearts (allograft dysfunction) in people who have had a heart transplant. Researchers are using cardiac MRI scans and a drug called Regadenoson to see how well blood flows to the heart muscle. They are also collecting blood and heart tissue samples to study the underlying causes at a molecular level. The main goal is to measure how well the heart's blood flow reserve works after 60 months. This study is currently recruiting adult heart transplant patients (18 years or older) who are at least three months post-transplant. The study aims to enroll 376 participants.

Study design
This is an interventional study, meaning participants will receive a specific intervention (Regadenoson). It plans to enroll 376 participants.
What's involved
You would undergo cardiac MRI scans, including stress imaging with intravenous Regadenoson and gadolinium contrast. Peripheral blood and endomyocardial biopsies will also be collected as part of your usual clinical care or if needed.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for at least 1 year after enrollment for major adverse cardiac events (MACE).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03102125

Allograft Dysfunction in Heart Transplant

Recruiting
PHASE4Ages 18+InterventionalDiagnostic
Paul Kim
~376 participants
Updated 2026-05-01 on ClinicalTrials.gov
What's tested:Regadenoson

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Myocardial Perfusion Reserve
Measured over 60 months

Conditions

Heart Transplant Failure and Rejection

Explore related trials

Heart Transplantation

NCT03102125

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UC San Diego

    La Jolla, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Paul Kim, MD · PRINCIPAL_INVESTIGATOR · UC San Diego

Who to contact

Paul Kim, MD
[email protected]
8582460638
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age greater than or equal to 18 years old.
At least three months status post heart transplantation.

Exclusion

Biopsy proven acute rejection episode in the past 3 months.
Patients with symptoms or signs of acute myocardial ischemia or recent acute coronary syndrome in the past 3 months.
Uncontrolled obstructive ventilatory disease including asthma and COPD.
History of generalized tonic-clonic seizures.
Second or third degree AV nodal block.
Sinus node dysfunction.
Contraindications to MRI including cardiovascular implantable electronic devices.
Renal dysfunction with an estimated GFR less than 30 mL/min/1.73m2.
Prior adverse reaction to either regadenoson or gadolinium contrast. Prior adverse reaction to adenosine or dipyridamole will be assessed on a case-by-case basis.
Systolic blood pressure greater than 180 or less than 85 mmHg.
Diastolic blood pressure greater than 120 or less than 40 mmHg.
Resting heart rate greater than 120 or less than 45 beats per minute. - Severe claustrophobia.

What this trial measures

  • Myocardial Perfusion Reserve60 months